Joinn Laboratories(China)Co.,Ltd. (SHA:603127)
China · Delayed Price · Currency is CNY 46.18
0.00 (0.00%)
Nov 11, 2026, 3:00 PM CST
SHA:603127 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,861 | 1,658 | 2,018 | 2,376 | 2,268 | 1,517 |
Revenue Growth | 11.54% | -17.87% | -15.07% | 4.78% | 49.54% | 40.97% |
Gross Profit Gross Profit Growth | 395.28 | 281.48 | 520.82 | 981.55 | 1,081 | 737.79 |
Operating Income Operating Income Growth | -41.53 | -128.93 | 83.69 | 573.16 | 708.41 | 415.82 |
Net Income Net Income Growth | 1,147 | 297.84 | 74.08 | 396.99 | 1,074 | 557.46 |
Earnings Per Share EPS Growth | 1.52 | 0.40 | 0.10 | 0.53 | 1.43 | 0.76 |
EPS Growth | 374.81% | 300.00% | -81.13% | -62.94% | 87.10% | 51.32% |
Fiscal Year | FY 2025 |
|---|---|
| Period Ending | Dec '25 Dec 31, 2025 |
Clinical Services and Others Clinical Services and Others Growth | 72.83 |
Non-Clinical Drug Research Services Non-Clinical Drug Research Services Growth | 1,577 |
Inter-Segment Offsets Inter-Segment Offsets Growth | -376.54 |
Supply of Experimental Models Supply of Experimental Models Growth | 384.29 |
Total Total Growth | 1,658 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 4,297 | 3,422 | 3,091 | 4,770 | 3,332 | 4,835 |
Total Debt Total Debt Growth | 37.09 | 21.6 | 60.97 | 69.42 | 87.71 | 95.32 |
Net Cash (Debt) Net Cash Growth | 4,260 | 3,400 | 3,030 | 4,700 | 3,245 | 4,740 |
Net Cash Growth | 26.78% | 12.21% | -35.53% | 44.87% | -31.55% | 806.03% |
Net Cash Per Share Net Cash Per Share Growth | 5.63 | 4.57 | 4.09 | 6.28 | 4.32 | 6.50 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 1,031 | 444.57 | 338.93 | 622.88 | 945.43 | 685.66 |
Capital Expenditures CapEx Growth | -453.25 | -143.6 | -269.39 | -192.72 | -268.75 | -237.24 |
Free Cash Flow Free Cash Flow Growth | 578.21 | 300.96 | 69.54 | 430.15 | 676.68 | 448.41 |
Free Cash Flow Growth | 174.68% | 332.81% | -83.83% | -36.43% | 50.91% | 60.49% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 21.25% | 16.98% | 25.80% | 41.30% | 47.68% | 48.64% |
Operating Margin | -2.23% | -7.78% | 4.15% | 24.12% | 31.24% | 27.42% |
Pretax Margin | 67.51% | 20.36% | 5.15% | 21.33% | 54.67% | 42.33% |
Profit Margin | 61.64% | 17.97% | 3.67% | 16.71% | 47.37% | 36.75% |
FCF Margin | 31.08% | 18.16% | 3.45% | 18.10% | 29.84% | 29.57% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.120 | 0.120 | 0.030 | 0.160 | 0.286 | 0.184 |
Dividend Per Share Growth | 300.00% | 300.00% | -81.25% | -44.00% | 55.61% | 43.89% |
Dividend Yield | 0.26% | 0.39% | 0.16% | 0.73% | 0.73% | 0.34% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 30.47 | 80.33 | 153.54 | 41.09 | 27.30 | 72.20 |
Forward PE | 46.44 | 75.53 | 47.64 | 19.41 | 30.58 | 77.82 |
P/FCF Ratio | 53.88 | 79.49 | 163.56 | 37.92 | 43.34 | 89.75 |
PS Ratio | 16.74 | 14.43 | 5.64 | 6.86 | 12.93 | 26.54 |